Dynamic Changes of Growth and Thyroid Function in Young Children With Chronic Hepatitis B Treated With Peginterferon Monotherapy.

IF 2.9 4区医学 Q3 IMMUNOLOGY

Pediatric Infectious Disease Journal Pub Date : 2024-10-01 DOI:10.1097/INF.0000000000004567

Qiufeng He, Chuangjie Mao, Zhili Chen, Fangfang Duan, Liang Huang, Rong Hu, Yang Deng, Jun Cheng, Song Yang, Yilan Zeng

{"title":"Dynamic Changes of Growth and Thyroid Function in Young Children With Chronic Hepatitis B Treated With Peginterferon Monotherapy.","authors":"Qiufeng He, Chuangjie Mao, Zhili Chen, Fangfang Duan, Liang Huang, Rong Hu, Yang Deng, Jun Cheng, Song Yang, Yilan Zeng","doi":"10.1097/INF.0000000000004567","DOIUrl":null,"url":null,"abstract":"Background: Peginterferon (PegIFN) has shown promising results in the treatment of chronic hepatitis B (CHB). This study aimed to evaluate the effects of PegIFN α-2b on growth and thyroid function in young children with CHB.Methods: A retrospective study was performed by extracting clinical data from children with CHB who received PegIFN α-2b monotherapy at the Public Health Clinical Center of Chengdu between June 2017 and December 2020. Mean, SD, independent samples t test and 1-way repeated analysis of variance were used to evaluate relevant data.Results: A total of 62 children were included in this study. Overall, significant differences were observed in the weight-for-age z score (WAZ), height-for-age z score (HAZ) and body mass index-for-age z score (BAZ) at different time points ( P < 0.001). WAZ, HAZ and BAZ were not affected by PegIFN α-2b at 24 weeks of treatment (all P > 0.05). WAZ, HAZ and BAZ at the end of treatment and 48 weeks after treatment; WAZ at 96 weeks after treatment were lower than baseline levels (all P < 0.05). No statistical differences were found in HAZ and BAZ at 96 weeks after treatment compared with baseline. Thyroid dysfunction developed in 17.7% of children during the treatment. Thyroid dysfunction was transient and had no effect on growth.Conclusions: PegIFN α-2b has inhibitory effects on growth and can increase the incidence of thyroid dysfunction in young children with CHB. These effects are generally reversible with the cessation of therapy, although WAZ had not returned to baseline after 96 weeks of observation.","PeriodicalId":19858,"journal":{"name":"Pediatric Infectious Disease Journal","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Infectious Disease Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/INF.0000000000004567","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Peginterferon (PegIFN) has shown promising results in the treatment of chronic hepatitis B (CHB). This study aimed to evaluate the effects of PegIFN α-2b on growth and thyroid function in young children with CHB.

Methods: A retrospective study was performed by extracting clinical data from children with CHB who received PegIFN α-2b monotherapy at the Public Health Clinical Center of Chengdu between June 2017 and December 2020. Mean, SD, independent samples t test and 1-way repeated analysis of variance were used to evaluate relevant data.

Results: A total of 62 children were included in this study. Overall, significant differences were observed in the weight-for-age z score (WAZ), height-for-age z score (HAZ) and body mass index-for-age z score (BAZ) at different time points ( P < 0.001). WAZ, HAZ and BAZ were not affected by PegIFN α-2b at 24 weeks of treatment (all P > 0.05). WAZ, HAZ and BAZ at the end of treatment and 48 weeks after treatment; WAZ at 96 weeks after treatment were lower than baseline levels (all P < 0.05). No statistical differences were found in HAZ and BAZ at 96 weeks after treatment compared with baseline. Thyroid dysfunction developed in 17.7% of children during the treatment. Thyroid dysfunction was transient and had no effect on growth.

Conclusions: PegIFN α-2b has inhibitory effects on growth and can increase the incidence of thyroid dysfunction in young children with CHB. These effects are generally reversible with the cessation of therapy, although WAZ had not returned to baseline after 96 weeks of observation.

查看原文本刊更多论文

接受聚乙二醇单药治疗的慢性乙型肝炎患儿生长和甲状腺功能的动态变化

背景：聚乙二醇干扰素（PegIFN）在治疗慢性乙型肝炎（CHB）方面取得了良好的效果。本研究旨在评估 PegIFN α-2b 对患有慢性乙型肝炎的幼儿的生长和甲状腺功能的影响：通过提取2017年6月至2020年12月期间在成都市公共卫生临床中心接受PegIFN α-2b单药治疗的CHB患儿的临床数据，进行了一项回顾性研究。采用均数、标准差、独立样本t检验和单因素重复方差分析评价相关数据：本研究共纳入62名儿童。总体而言，不同时间点的体重-年龄 Z 值（WAZ）、身高-年龄 Z 值（HAZ）和体重指数-年龄 Z 值（BAZ）均存在明显差异（P < 0.001）。治疗 24 周时，WAZ、HAZ 和 BAZ 均不受 PegIFN α-2b 的影响（均 P > 0.05）。治疗结束时和治疗 48 周后的 WAZ、HAZ 和 BAZ，以及治疗 96 周后的 WAZ 均低于基线水平（所有 P <0.05）。治疗后 96 周的 HAZ 和 BAZ 与基线相比无统计学差异。17.7%的儿童在治疗期间出现甲状腺功能障碍。甲状腺功能障碍是短暂的，对生长没有影响：结论：PegIFN α-2b对CHB患儿的生长有抑制作用，并可增加甲状腺功能障碍的发生率。尽管在观察96周后WAZ仍未恢复到基线，但停止治疗后这些影响通常是可逆的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Infectious Disease Journal 医学-传染病学

CiteScore

6.30

自引率

2.80%

发文量

566

审稿时长

2-4 weeks

期刊介绍： The Pediatric Infectious Disease Journal® (PIDJ) is a complete, up-to-the-minute resource on infectious diseases in children. Through a mix of original studies, informative review articles, and unique case reports, PIDJ delivers the latest insights on combating disease in children — from state-of-the-art diagnostic techniques to the most effective drug therapies and other treatment protocols. It is a resource that can improve patient care and stimulate your personal research.